Browse the evidence

BHB supplementation led to a reduction in LDL cholesterol in the BHB group.

BHB supplementation may improve lipid profiles in overweight and obese individuals.

GLP-1RAs improve blood pressure regulation and lipid metabolism.

Incorporating GLP-1RAs may enhance management of blood pressure and lipid levels in diabetic patients.

Diabetes remission rates reach 78% for Roux-en-Y gastric bypass (RYGB) and 62% for sleeve gastrectomy (SG).

Bariatric surgery can be an effective treatment for diabetes in obese patients.

Weight gain among persons with HIV on contemporary antiretroviral therapy can lead to overweight/obesity in the first 1 to 2 years, resulting in enhanced cardiometabolic risk.

Healthcare providers should monitor weight changes in persons with HIV on ART to mitigate cardiometabolic risks.

A thorough preoperative evaluation is essential to optimize outcomes and minimize risks for body contouring procedures after significant weight loss.

Practitioners should ensure thorough evaluations before body contouring surgeries.

Semaglutide represents a practice-changing therapy that addresses core pathophysiological drivers of ASCVD and HFpEF through integrated modulation of adiposity and metabolic dysfunction.

Clinicians should consider semaglutide as a key treatment option for managing ASCVD and HFpEF.

Weight cycling (yo-yo dieting) may be detrimental to metabolism, eating behaviors, quality of life, and mortality rate.

Practitioners should consider the potential negative effects of weight cycling on overall health.

Metabolic and bariatric surgery (MBS) is the most effective long-term treatment for severe obesity and its associated comorbidities.

MBS should be considered as a primary treatment option for patients with severe obesity.

MBS is associated with improved glycemic and metabolic control, lower apnea burden, reduced risk of major adverse cardiovascular events, and improved overall survival.

MBS can significantly improve health outcomes for patients with severe obesity.

Endoluminal bariatric and metabolic therapies have expanded significantly, with FDA-approved therapies available for patients with a body mass index as high as 50 kg/m².

Practitioners should consider these therapies for patients with high BMI who may not qualify for traditional bariatric surgery.

Responders to the PF regimen exhibited enhanced metabolic flexibility compared to non-responders.

Personalized dietary interventions may enhance metabolic flexibility in patients with T2D.

Stroke is inversely associated with fat intake from supplements and PUFA intake from diet.

Increasing intake of specific fats, particularly PUFA, may help in stroke prevention.

Higher consumption of animal-based foods may mitigate the risk of elevated TyG among women.

Encouraging a balanced intake of animal-based foods may be beneficial for women at risk of elevated TyG.

Diet composition influences energy expenditure, energy partitioning, and appetite control.

Practitioners should consider diet composition beyond just macronutrients.

Glucose metrics continued to decline after week 1 in high-carbohydrate diets.

High-carbohydrate diets may lead to improved glucose metrics over time.

The number of participants with abnormal glucose tolerance decreased in high-carbohydrate groups.

Transitioning to a high-carbohydrate diet may improve glucose tolerance in individuals.

Glucose metrics continued to decline after week 1 in high-carbohydrate diets.

Monitoring glucose metrics can provide insights into the effectiveness of dietary changes.

The number of participants with abnormal glucose tolerance decreased in high-carbohydrate groups.

High-carbohydrate diets may improve glucose tolerance in individuals transitioning from low-carbohydrate diets.

Parameters of glucose metabolism improved as a result of the course.

Improving glucose metabolism can be a beneficial outcome of weight loss programs.

Parameters of glucose metabolism improved along with psychological indicators of eating impulses.

Improving glucose metabolism and psychological factors can enhance weight loss strategies.

Both 0839 and 0833 improved metabolic parameters and reduced body weight primarily by fat mass reduction.

These compounds may be effective for fat loss and improving metabolic health.

Optimal obesity management requires a systematic assessment that extends beyond body mass index (BMI).

Clinicians should incorporate comprehensive assessments in obesity management.

Obesity is a significant pathogenic factor for multiple chronic conditions and ranks as the sixth leading risk factor for mortality and disability nationwide.

Healthcare practitioners should recognize obesity as a critical factor in managing chronic diseases.

Dual agonists represent a transformative therapeutic class for metabolic disease management.

Clinicians should consider dual agonists as a key component in the management of metabolic diseases.